Topic: Pharmacokinetics

John Fleetwood provides a detailed breakdown of the FDA insert for the Ervebo Ebola vaccine. He cites page 11, section 12.3, which explicitly lists "shedding" as a factor, occurring in 31.7% of subjects. The insert also confirms that the vaccine has not been tested for carcinogenicity, genotoxicity, or its effects on male and female fertility.

Dr. Ruby argues that the inserts are blank because the necessary human safety and pharmacokinetic studies were never completed. She expresses concern that the FDA will eventually grant full approval despite these missing data points, driven by political and corporate pressure.